Skip to main content

Table 1 Baseline characteristics of 33 eyes treated with IVTA stratified with respect of change in IOP from baseline

From: Intraocular pressure rise is predictive of vision improvement after intravitreal triamcinolone acetonide for diabetic macular oedema: a retrospective analysis of data from a randomised controlled trial

Characteristic IOP change < 5 mmHg rise IOP rise 5–9 mmHg IOP rise ≥ 10 mmHg P value
(n = 17) (n = 8) (n = 8)
Age (y) 63.8 ± 8.4 63.9 ± 15.7 61.5 ± 7.2 0.864
Gender, female (n) 9 (53%) 4 (50%) 2 (25%) 0.440
HbA1c a 7.9 ± 1.2 9.1 ± 1.5 8.2 ± 1.5 0.295
Phakia, pseudophakic (n) 3 (18%) 2 (25%) 1 (14%) 0.862
IOP (mmHg) 16.9 ± 2.4 15.8 ± 3.1 16.6 ± 2.6 0.600
BCVA (letters) 60.1 ± 14.0 62.9 ± 6.7 58.5 ± 12.7 0.771
CMT (μm) b 436 ± 146 443 ± 132 468 ± 22 0.916
  1. IVTA = intravitreal triamcinolone; IOP = intraocular pressure; BCVA = best-corrected visual acuity; CMT = central macular thickness.
  2. Values are mean ± standard deviation or median with interquartile range shown in box brackets.
  3. an = 13, 4 and 7 for IOP rise <5 mmHg, 5-9 mmHg and ≥10 mmHg, respectively.
  4. bn = 12, 5 and 4 for IOP rise <5 mmHg, 5-9 mmHg and ≥10 mmHg, respectively.